ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Colistin therapy and survival outcomes in neonatal carbapenem-resistant gram-negative sepsis.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Gram-negative (CR-GN) sepsis is a growing cause of neonatal mortality, especially in low- and middle-income countries. Colistin remains one of the few effective therapeutic options.
methodsThis retrospective cohort study reviewed hospital files of inborn neonates admitted within six hours of birth to the neonatal intensive care unit (NICU) of Imam Khomeini Hospital, Ahvaz, Iran (March 2019-March 2023), with blood culture-proven CR-GN sepsis. Blood cultures were obtained from peripheral samples and processed in Trypticase Soy Broth; isolates were identified and antibiotic susceptibility determined using the Kirby-Bauer disk diffusion method per Clinical and Laboratory Standards Institute (CLSI) guidelines. Because colistin disks were unavailable, clinical and microbiological responses were used to evaluate efficacy. Neonates received either a colistin-containing regimen (colistin + meropenem) or a non-colistin regimen (amikacin + meropenem). Univariate logistic regression was performed, and a sensitivity analysis limited to survivors was conducted for length-of-stay comparison.
resultsThe hospital records of 108 neonates were analyzed (36 colistin-treated, 72 non-colistin-treated). Acinetobacter spp. were the most frequent isolate. Among infants who received colistin, the rate of late-onset sepsis was significantly higher than that of early-onset sepsis (69.4% vs. 25.0%, p < 0.001). The mortality rate was significantly lower in the colistin group (41.7% vs. 70.8%, p = 0.006).
conclusionA colistin-containing regimen was associated with significantly improved survival among neonates with CR-GN sepsis. Despite limitations in susceptibility testing, these findings underscore the clinical value of colistin in resource-limited NICUs, warranting prospective validation of dosing, safety, and antimicrobial stewardship strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.